USP Workshops Address Variety of Pharma Issues
The US Pharmacopeial Convention is hosting a variety of workshops in Autumn 2017 on a wide range of topics including continuing education, bioassays, and peptides.
The US Pharmacopeial Convention (USP) will be hosting five workshops in the fall of 2017 that will address current scientific findings, regulatory trends, and public health issues. The workshops are open to anyone interested, and more information can be found on USP’s website.
The following workshops are available:
- Re-thinking Pharmaceutical Technology Continuing Education, Sept. 14–15, 2017. This workshop, cosponsored by the National Institute for Pharmaceutical Technology and Education (NIPTE), will include presentations on NIPTE training programs and USP’s standardization and educational programs. Topics discussed will include pharmaceutical continuing education and education best practices.
- USP’s 7th Bioassay Workshop–Bioassay: A Lifecycle Approach, Sept. 25–26, 2017. This workshop will take a look at how lifecycle and QbD perspectives are being incorporated into bioassays. Lifecycle methods from scientific, statistical, and regulatory perspectives will be discussed.
- Computer Modeling–In-vitro and In-vivo Studies, Oct. 23–25, 2017. This workshop will address how computer modeling and simulation can be useful tools to accelerate product development.
- IPA Probiotic Workshop in DC, Oct. 26, 2017. Cosponsored by the International Probiotics Association, this workshop will foster open dialogue on how probiotics may be considered within regulations.
- 4th USP Workshop on Synthetic Therapeutic Peptides: Regulations, Standards and Quality, Nov. 6–7, 2017. Attendees will learn about USP’s standards and regulatory expectations for peptide products. Strategies for control of raw materials and impurities will be discussed.
Visit www.usp.org for more information.
Source: USP
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
